A study to compare 2 injection treatments in knee osteoarthritis, that is, Platelet Rich Plasma (derived from own blood) and Adalimumab (drug) injection into knee joint to find out improvement in pain, betterment of quality of life and improvement in performing activities of daily living.

Comparison between intraarticular Platelet Rich Plasma and Adalimumab in improvement of pain, quality of life and activities of daily living in patients with primary osteoarthritis knee - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055429

Enrollment

Registered

2023-07-20

Start date

Unknown

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: Intraarticular Adalimumab in primary osteoarthritis knee patients: Patients will be recruited after considering inclusion criteria and exclusion criteria. After obtaining informed cons

Eligibility

Inclusion criteria

Inclusion criteria: INCLUSION CRITERIA : 1.Patients diagnosed with OA of knee based on American College of Rheumatology criteria 2.Radiologic KL grade II & III 3. VAS Score > 40 4. Patients not showing improvement with conservative treatment using NSAIDs for 3 months 5.Patients willing for follow up

Exclusion criteria

Exclusion criteria: EXCLUSION CRITERIA : 1. Patients with cognitive impairment and psychiatric disorders 2. Local site infections 3. Uncontrolled diabetes 4.Presence of other rheumatologic conditions, autoimmune diseases and collagen vascular disease 5.Coagulation disorders and disorders affecting platelet 6. Active and latent tuberculosis 7. History of active, recurrent or chronic infections 8. Congestive heart failure (NYHA class III and IV) 9. Immunocompromised (HIV, Patients on immunosuppresants, transplant recipients) 10. Previous use of TNF alpha inhibitors for Knee OA 11. Platelet 12. Prior knee injections (like cortcosteroid, HA or prolotherapy) in past 3 months 13. Previous knee surgery 14..Use of systemic steroids within past 3 months 15. Malignancy 16. Pregnancy and lactation 17. Individuals who refused to participate

Design outcomes

Primary

Measure	Time frame
Primary outcome measures included were changes in : 1. Pain intensity measured with VAS score Secondary outcome measures included were improvement in : 1. Quality of life and activities of daily living measured with the help of KOOS scale at baseline, 6 weeks, 3 months and 6 months post injection.Timepoint: Primary outcome measures included were changes in : 1. Pain intensity measured with VAS score Secondary outcome measures included were improvement in : 1. Quality of life and activities of daily living measured with the help of KOOS scale at baseline, 6 weeks, 3 months and 6 months post injection.	—

Measure

Time frame

Primary outcome measures included were changes in : 1. Pain intensity measured with VAS score Secondary outcome measures included were improvement in : 1. Quality of life and activities of daily living measured with the help of KOOS scale at baseline, 6 weeks, 3 months and 6 months post injection.Timepoint: Primary outcome measures included were changes in : 1. Pain intensity measured with VAS score Secondary outcome measures included were improvement in : 1. Quality of life and activities of daily living measured with the help of KOOS scale at baseline, 6 weeks, 3 months and 6 months post injection.

—

Secondary

Measure	Time frame
No secondary outcome measuredTimepoint: Not applicable	—

Countries

India

Contacts

Public ContactDarshana S

All India Institute of Medical Sciences, New Delhi

slyaiims59@gmail.com9560678577

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026